Literature DB >> 12686037

Cervical cancer and use of hormonal contraceptives: a systematic review.

Jennifer S Smith1, Jane Green, Amy Berrington de Gonzalez, Paul Appleby, Julian Peto, Martyn Plummer, Silvia Franceschi, Valerie Beral.   

Abstract

BACKGROUND: Human papillomavirus (HPV) is believed to be the most important cause of cervical cancer. Recent studies suggest that long duration use of oral contraceptives increases the risk of cervical cancer in HPV positive women.
METHODS: Results from published studies were combined to examine the relationship between invasive and in situ cervical cancer and duration and recency of use of hormonal contraceptives, with particular attention to HPV infection.
FINDINGS: 28 eligible studies were identified, together including 12531 women with cervical cancer. Compared with never users of oral contraceptives, the relative risks of cervical cancer increased with increasing duration of use: for durations of approximately less than 5 years, 5-9 years, and 10 or more years, respectively, the summary relative risks were 1.1 (95% CI 1.1-1.2), 1.6 (1.4-1.7), and 2.2 (1.9-2.4) for all women; and 0.9 (0.7-1.2), 1.3 (1.0-1.9), and 2.5 (1.6-3.9) for HPV positive women. The results were broadly similar for invasive and in situ cervical cancers, for squamous cell and adenocarcinoma, and in studies that adjusted for HPV status, number of sexual partners, cervical screening, smoking, or use of barrier contraceptives. The limited available data suggest that the relative risk of cervical cancer may decrease after use of oral contraceptives ceases. However, study designs varied and there was some heterogeneity between study results.
INTERPRETATION: Although long duration use of hormonal contraceptives is associated with an increased risk of cervical cancer, the public health implications of these findings depend largely on the extent to which the observed associations remain long after use of hormonal contraceptives has ceased, and this cannot be evaluated properly from published data.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12686037     DOI: 10.1016/s0140-6736(03)12949-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  65 in total

Review 1.  Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications.

Authors:  Meike Ressing; Maria Blettner; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2009-07-03       Impact factor: 5.594

2.  A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA.

Authors:  Cairong Zhu; Bryan A Bassig; Yawei Zhang; Kunchong Shi; Peter Boyle; Ni Li; Tongzhang Zheng
Journal:  Eur J Cancer Prev       Date:  2015-05       Impact factor: 2.497

3.  HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress.

Authors:  Vonetta M Williams; Maria Filippova; Ubaldo Soto; Penelope J Duerksen-Hughes
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

Review 4.  Contraception in women over 40 years of age.

Authors:  Rebecca H Allen; Carrie A Cwiak; Andrew M Kaunitz
Journal:  CMAJ       Date:  2013-03-04       Impact factor: 8.262

Review 5.  Application of electrospun fibers for female reproductive health.

Authors:  Anna K Blakney; Yonghou Jiang; Kim A Woodrow
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

Review 6.  Human papillomavirus infection and the multistage carcinogenesis of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

7.  Assessing the relationship between HIV infection and cervical cancer in Côte d'Ivoire: a case-control study.

Authors:  Georgette Adjorlolo-Johnson; Elizabeth R Unger; Edith Boni-Ouattara; Kadidiata Touré-Coulibaly; Chantal Maurice; Suzanne D Vernon; Marcel Sissoko; Alan E Greenberg; Stefan Z Wiktor; Terence L Chorba
Journal:  BMC Infect Dis       Date:  2010-08-17       Impact factor: 3.090

8.  Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study.

Authors:  Philip C Hannaford; Sivasubramaniam Selvaraj; Alison M Elliott; Valerie Angus; Lisa Iversen; Amanda J Lee
Journal:  BMJ       Date:  2007-09-11

Review 9.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

10.  Estradiol modulation of hepatocyte growth factor by stromal fibroblasts in the female reproductive tract.

Authors:  Kimberly D Coleman; Jacqueline A Wright; Mimi Ghosh; Charles R Wira; John V Fahey
Journal:  Fertil Steril       Date:  2009-05-06       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.